EC approval for BI/Lilly's one-dosage Trajenta for type 2 diabetes
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim and Eli Lilly have won marketing authorisation from the European Commission for their once-daily, one dosage-strength type 2 diabetes treatment, Trajenta (linagliptin).